Zealand Pharma wins EU approval for glepaglutide in short bowel syndrome

The European Commission has granted marketing authorisation for Zeydovio, the first ready-to-use GLP-2 therapy approved for short bowel syndrome in Europe.

A gloved hand holds a white medical diagnostic tool with a grey clip and slider, in a brightly lit hospital room with a bed rail and blurred medical equipment in the background.

Zealand Pharma has secured European Commission marketing authorisation for Zeydovio (glepaglutide), a long-acting GLP-2 analogue, for the treatment of adults with short bowel syndrome (SBS). The approval, valid across all EU member states as well as Iceland, Liechtenstein, and Norway, is the first regulatory green light in Europe for a ready-to-use GLP-2 therapy and, the company says, the first meaningful advance in the treatment landscape in more than a decade.

Short bowel syndrome is a rare, chronic condition in which reduced or absent intestinal function leaves patients dependent on parenteral support (PS) for nutrition and fluid delivery. That dependency carries substantial risk: patients face serious complications including sepsis, blood clots, liver damage, and renal impairment, alongside significant restrictions on daily life. The condition is classified as an orphan disease in both the EU and the US, the latter confirmed by the FDA's orphan drug designation granted to glepaglutide.

Clinical foundation

The approval rests primarily on the pivotal EASE-1 Phase 3 trial, which enrolled 106 adults with SBS and intestinal failure who were dependent on PS for at least three days per week. Patients receiving glepaglutide twice weekly reduced total weekly PS volume by 5.13 litres compared with 2.85 litres in the placebo group at 24 weeks (p=0.0039). Among twice-weekly recipients, 65.7% achieved a clinical response, defined as at least a 20% reduction in weekly PS volume, versus 38.9% in the placebo arm. Nine patients treated with glepaglutide achieved enteral autonomy, meaning complete independence from parenteral support; no placebo-treated patient achieved this outcome.

Supporting data from the EASE-2, EASE-3, and EASE-4 extension and mechanistic trials strengthened the application. EASE-4 demonstrated a mean increase in intestinal wet weight absorption of 398 g/day at week 24 and a reduction in PS volume of 800 mL/day by week 52. Full EASE-2 and EASE-3 results are expected to be presented at scientific meetings in 2027.

Commercial and regulatory outlook

Zealand Pharma has not yet named a commercial partner for European distribution and has confirmed it is in active partnership discussions. The search for a licensee is a key near-term milestone investors will be tracking, given that the company is simultaneously funding the ongoing EASE-5 Phase 3 trial in the US. EASE-5 is designed to generate the confirmatory evidence needed to support a New Drug Application with the FDA; enrolment is described as progressing well.

Adam Steensberg, President and Chief Executive Officer of Zealand Pharma, said the company's focus would now turn to "finding the right partner to bring Zeydovio to as many people living with short bowel syndrome as possible across Europe and beyond."

Market context

Glepaglutide enters a GLP-2 market where Takeda's teduglutide (Revestive in Europe, Gattex in the US) has been the established standard of care. Teduglutide requires daily subcutaneous injection; glepaglutide's twice-weekly dosing via a ready-to-use autoinjector is the differentiating convenience claim Zealand is positioning prominently. That said, payer willingness to reimburse premium-priced orphan biologics at scale across European health systems will be a material commercial variable, and the absence of head-to-head data against teduglutide means the comparative clinical story remains incomplete. The GLP-2 class has also attracted renewed interest in the context of broader GLP receptor research, though glepaglutide's orphan positioning keeps it in a narrow indication for now. Full long-term efficacy and safety data from EASE-2 and EASE-3, expected in 2027, will be watched closely by both regulators and prescribers as the commercialisation effort ramps up.